OBJECTIVES: We investigated the efficacy and safety of using balloon expandable drug-eluting stents (DES) to prevent amputations in patients with below-the-knee critical limb ischemia. BACKGROUND: Critical limb ischemia patients have a 1-year amputation rate of 30% and a mortality rate of 25%. Most patients with critical limb ischemia have severe below-the-knee arterial disease that limits the use of bypass surgery or balloon angioplasty. METHODS: In all, 106 patients (118 limbs) were treated with DES in this prospective, nonrandomized trial. No patients were excluded because of comorbidities or unfavorable anatomy. Primary end points were major amputation and mortality, each stratified by Rutherford category. RESULTS: The mean patient age was 74 +/- 9 years. There were 228 DES implanted (83% Cypher [Cordis, Johnson & Johnson, Warren, New Jersey], 17% Taxus [Boston Scientific, Maple Grove, Minnesota]). The number of stents per limb was 1.9 +/- 0.9, and 35% of limbs received overlapping DES (length of 60 +/- 13 mm). There were no procedural deaths, and 96% of patients were discharged within 24 h. The 3-year cumulative incidence of amputation was 6 +/- 2%, survival was 71 +/- 5%, and amputation-free-survival was 68 +/- 5%. Only 12% of patients who died had a preceding major amputation. Rutherford category, age, creatinine level, and dialysis (p <or= 0.001 to 0.04) were predictors of death but not amputation. Target limb revascularization occurred in 15% of patients, and repeat angiography in 35% of patients revealed a binary restenosis in 12%. CONCLUSIONS: Treating below-the-knee critical limb ischemia with DES is an effective and safe means of preventing major amputation and relieving symptoms. Procedural complications and limb revascularization rates were low. Limb salvage and survival rates in patients treated with DES exceed those of historic controls. Copyright (c) 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
OBJECTIVES: We investigated the efficacy and safety of using balloon expandable drug-eluting stents (DES) to prevent amputations in patients with below-the-knee critical limb ischemia. BACKGROUND:Critical limb ischemiapatients have a 1-year amputation rate of 30% and a mortality rate of 25%. Most patients with critical limb ischemia have severe below-the-knee arterial disease that limits the use of bypass surgery or balloon angioplasty. METHODS: In all, 106 patients (118 limbs) were treated with DES in this prospective, nonrandomized trial. No patients were excluded because of comorbidities or unfavorable anatomy. Primary end points were major amputation and mortality, each stratified by Rutherford category. RESULTS: The mean patient age was 74 +/- 9 years. There were 228 DES implanted (83% Cypher [Cordis, Johnson & Johnson, Warren, New Jersey], 17% Taxus [Boston Scientific, Maple Grove, Minnesota]). The number of stents per limb was 1.9 +/- 0.9, and 35% of limbs received overlapping DES (length of 60 +/- 13 mm). There were no procedural deaths, and 96% of patients were discharged within 24 h. The 3-year cumulative incidence of amputation was 6 +/- 2%, survival was 71 +/- 5%, and amputation-free-survival was 68 +/- 5%. Only 12% of patients who died had a preceding major amputation. Rutherford category, age, creatinine level, and dialysis (p <or= 0.001 to 0.04) were predictors of death but not amputation. Target limb revascularization occurred in 15% of patients, and repeat angiography in 35% of patients revealed a binary restenosis in 12%. CONCLUSIONS: Treating below-the-knee critical limb ischemia with DES is an effective and safe means of preventing major amputation and relieving symptoms. Procedural complications and limb revascularization rates were low. Limb salvage and survival rates in patients treated with DES exceed those of historic controls. Copyright (c) 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Authors: Michael R Jaff; Christopher J White; William R Hiatt; Gerry R Fowkes; John Dormandy; Mahmood Razavi; Jim Reekers; Lars Norgren Journal: Ann Vasc Dis Date: 2015-10-23
Authors: Gagan D Singh; Ehrin J Armstrong; Khung-Keong Yeo; Satinder Singh; Gregory G Westin; William C Pevec; David L Dawson; John R Laird Journal: J Vasc Surg Date: 2014-01-03 Impact factor: 4.268
Authors: Maria Teresa B Abola; Jonathan Golledge; Tetsuro Miyata; Seung-Woon Rha; Bryan P Yan; Timothy C Dy; Marie Simonette V Ganzon; Pankaj Kumar Handa; Salim Harris; Jiang Zhisheng; Ramakrishna Pinjala; Peter Ashley Robless; Hiroyoshi Yokoi; Elaine B Alajar; April Ann Bermudez-Delos Santos; Elmer Jasper B Llanes; Gay Marjorie Obrado-Nabablit; Noemi S Pestaño; Felix Eduardo Punzalan; Bernadette Tumanan-Mendoza Journal: J Atheroscler Thromb Date: 2020-07-04 Impact factor: 4.928
Authors: Sanjay Misra; Robert Lookstein; John Rundback; Alan T Hirsch; William R Hiatt; Michael R Jaff; Christopher R White; Michael Conte; Patrick Geraghty; Manesh Patel; Kenneth Rosenfield Journal: J Vasc Interv Radiol Date: 2013-04 Impact factor: 3.464
Authors: Dominic P J Howard; Amitava Banerjee; Jack F Fairhead; Linda Hands; Louise E Silver; Peter M Rothwell Journal: Circulation Date: 2015-09-08 Impact factor: 29.690
Authors: Agnieszka Jazwa; Jacek Stepniewski; Martin Zamykal; Jolanta Jagodzinska; Marco Meloni; Costanza Emanueli; Alicja Jozkowicz; Jozef Dulak Journal: Cardiovasc Res Date: 2012-10-19 Impact factor: 10.787